PHARMACEUTICAL 2023

Nektar Therapeutics
Rank 282 of 471



PHARMACEUTICAL 2023

Nektar Therapeutics
Rank 282 of 471

The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 34% points.The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 215%, being 30% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	545,968
Cost of Goods Sold	21,635
Intangible Assets	76,501
Liabilities, Current	68,204
Liabilities, Non-Current	120,380
Other Assets	55,680
Other Compr. Net Income	-2,750
Other Expenses	139,145
Other Liabilities	155,378
Other Net Income	11,183
Other Revenues	92,055
Property and Equipment	32,451
Research and Development	218,323
Selling, General and Administrative Expense	92,333

Output Variable	Value in 1000 USD
Assets	710,600
Liabilities	343,962
Expenses	471,436
Revenues	92,055
Stockholders Equity	366,638
Net Income	-368,198
Comprehensive Net Income	-369,573
BaseVar	815,993
ECR before LimitedLiability	81%
Economic Capital Ratio	215%